Thermo Fisher Scientific Inc. $TMO Shares Sold by Mirova US LLC

Mirova US LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 687,066 shares of the medical research company’s stock after selling 101,873 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.9% of Mirova US LLC’s investment portfolio, making the stock its 15th largest position. Mirova US LLC’s holdings in Thermo Fisher Scientific were worth $278,578,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares in the last quarter. Root Financial Partners LLC increased its position in shares of Thermo Fisher Scientific by 5.0% in the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock valued at $252,000 after buying an additional 24 shares in the last quarter. Rossmore Private Capital increased its position in shares of Thermo Fisher Scientific by 0.5% in the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock valued at $2,315,000 after buying an additional 24 shares in the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its position in shares of Thermo Fisher Scientific by 3.1% in the second quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock valued at $326,000 after buying an additional 24 shares in the last quarter. Finally, Family Legacy Inc. increased its position in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Family Legacy Inc. now owns 2,690 shares of the medical research company’s stock valued at $1,339,000 after buying an additional 26 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company’s stock, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 in the last quarter. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on TMO shares. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective for the company in a research report on Friday, July 11th. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Barclays boosted their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Raymond James Financial reiterated an “outperform” rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $591.16.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $539.54 on Wednesday. The stock’s fifty day moving average is $484.90 and its two-hundred day moving average is $447.60. The firm has a market capitalization of $203.73 billion, a P/E ratio of 31.21, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.